|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项比较[18F]APN-1607注射液正电子发射断层扫描用于阿尔兹海默病受试者和健康老年受试者的III期、多中心临床研究
[Translation] A Phase III, Multicenter Clinical Study Comparing [18F]APN-1607 Injection with Positron Emission Tomography in Subjects with Alzheimer's Disease and Healthy Elderly Subjects
本方案的总体研究目的是评价[18F]APN-1607 PET评估纤维性Tau蛋白沉积的效用,包括评估[18F]APN-1607在认知功能正常、老年健康个体(即健康老年受试者)、轻度认知功能障碍受试者和阿尔茨海默病痴呆受试者的安全性和耐受性,以及评价并比较[18F]APN-1607在上述人群中的摄取模式。
[Translation] The overall study objectives of this protocol are to evaluate the utility of [18F]APN-1607 PET in assessing fibrillary tau deposition, including evaluating the safety and tolerability of [18F]APN-1607 in cognitively normal, healthy elderly individuals (i.e., healthy elderly subjects), subjects with mild cognitive impairment, and subjects with Alzheimer's disease dementia, and to evaluate and compare the uptake patterns of [18F]APN-1607 in the above populations.
100 Clinical Results associated with Suzhou Xinxu Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Suzhou Xinxu Pharmaceutical Co., Ltd.
100 Deals associated with Suzhou Xinxu Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Suzhou Xinxu Pharmaceutical Co., Ltd.